Table 4 Urinary beta 3-adrenoceptor/Cr levels in normal controls, OAB Baseline and subgroups.

From: Urinary beta 3-adrenoceptor as a diagnostic biomarker for overactive bladder in women

 

Urinary beta-3 adrenoceptor/Cr (pg/mg)

p valuea

Overallb

 Normal (n = 35)

1.98 ± 0.90

 

 Total OAB baseline (n = 50)c

1.25 ± 0.70

 < 0.001*

 Treated OAB baseline (n = 23)d

1.25 ± 0.76

0.011*

OAB Baseline

 

0.748

 Non-treated OAB (n = 27)

1.25 ± 0.66

 

 Treated OAB (n = 23)

1.25 ± 0.76

 

Types of Subgroup—OAB Baseline (n = 50)

 

0.861

 Detrusor overactivity (n = 11)

1.22 ± 0.73

 

 Hypersensitive bladder (n = 39)

1.26 ± 0.71

 

Types of Subgroup—Treated OAB (n = 23)

 

0.456

 Detrusor overactivity (n = 5)

1.41 ± 0.76

 

 Hypersensitive bladder (n = 18)

1.20 ± 0.78

 

Treated OAB

 

 < 0.001*

 OAB before treatment (n = 23)

1.25 ± 0.76

 

 OAB after treatment (n = 23)

4.41 ± 3.72

 

Before treatment

 

0.401

 Successful treatment (n = 17)

1.20 ± 0.84

 

 Unsatisfactory result (n = 6)

1.40 ± 0.54

 

After treatment

 

0.010*

 Successful treatment (n = 17)

5.35 ± 3.88

 

 Unsatisfactory result (n = 6)

1.73 ± 1.04

 
  1. Data are presented as mean ± standard deviation.
  2. aMann–Whitney U-test.
  3. bKruskal–Wallis test.
  4. cMann–Whitney U-test, Normal vs Total OAB baseline.
  5. dMann–Whitney U-test, Normal vs Treated OAB baseline.
  6. *p < 0.05.
Back to article page